within Pharmacolibrary.Drugs.ATC.S;

model S01XA02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 7.5e-06,
    adminDuration  = 600,
    adminMass      = 5000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01XA02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Retinol, also known as vitamin A1, is a fat-soluble vitamin essential for vision, immune function, and cellular growth. Pharmaceutical retinol is used mainly as a supplement to treat or prevent vitamin A deficiency and is sometimes used topically for dermatological purposes. It is not typically approved as a drug for therapeutic indications except for addressing deficiencies.</p><h4>Pharmacokinetics</h4><p>No original publications were found reporting detailed pharmacokinetic parameters of retinol (vitamin A), especially for ophthalmic or systemic use in healthy adults or other populations. The following values are estimated based on general knowledge of oral retinol pharmacokinetics from vitamin A supplementation literature.</p><h4>References</h4><ol><li><p>Schmitt-Hoffmann, AH, et al., &amp; Kovacs, P (2012). Oral alitretinoin: a review of the clinical pharmacokinetics and pharmacodynamics. <i>Expert review of clinical pharmacology</i> 5(4) 373–388. DOI:<a href=&quot;https://doi.org/10.1586/ecp.12.26&quot;>10.1586/ecp.12.26</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22943117/&quot;>https://pubmed.ncbi.nlm.nih.gov/22943117</a></p></li><li><p>Peng, YM, et al., &amp; Meyskens, FL (1989). Pharmacokinetics of N-4-hydroxyphenyl-retinamide and the effect of its oral administration on plasma retinol concentrations in cancer patients. <i>International journal of cancer</i> 43(1) 22–26. DOI:<a href=&quot;https://doi.org/10.1002/ijc.2910430106&quot;>10.1002/ijc.2910430106</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2521335/&quot;>https://pubmed.ncbi.nlm.nih.gov/2521335</a></p></li><li><p>Garofoli, F, et al., &amp; Stronati, M (2018). Levels and effectiveness of oral retinol supplementation in VLBW preterm infants. <i>International journal of immunopathology and pharmacology</i> 32 2058738418820484–None. DOI:<a href=&quot;https://doi.org/10.1177/2058738418820484&quot;>10.1177/2058738418820484</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30897987/&quot;>https://pubmed.ncbi.nlm.nih.gov/30897987</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01XA02;
